Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma HELP
Based on 32,740 articles published since 2009
|||| 16 

These are the 32740 published articles about Melanoma that originated from Worldwide during 2009-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
351 Editorial A house of cards. 2012

McCalmont, Timothy H. · ·J Cutan Pathol · Pubmed #22845657.

ABSTRACT: -- No abstract --

352 Editorial Metal-on-metal hip implants and the risk of cancer. 2012

Rosengren, Bjorn Erik. · ·BMJ · Pubmed #22833625.

ABSTRACT: -- No abstract --

353 Editorial Compare and contrast. 2012

Anonymous2750732. · ·Prescrire Int · Pubmed #22822589.

ABSTRACT: -- No abstract --

354 Editorial Uveal melanoma trapped in the temple of doom. 2012

Shields, Carol L / Ganguly, Arupa / O'Brien, Joan / Sato, Takami / Shields, Jerry A. · ·Am J Ophthalmol · Pubmed #22813447.

ABSTRACT: -- No abstract --

355 Editorial Can we better identify thin cutaneous melanomas that are likely to metastasize and cause death? 2012

Murali, Rajmohan / Scolyer, Richard A / Thompson, John F. · ·Ann Surg Oncol · Pubmed #22777079.

ABSTRACT: -- No abstract --

356 Editorial Skin cancer in skin of color. 2012

Alexis, Andrew F / Rossi, Anthony M. · ·Cutis · Pubmed #22768430.

ABSTRACT: -- No abstract --

357 Editorial Identifying melanomas in primary care: can we do better? 2012

Newton-Bishop, Julia / Lorigan, Paul. · ·BMJ · Pubmed #22763394.

ABSTRACT: -- No abstract --

358 Editorial When transgenes shape immunity: cancer immune-gene therapy. 2012

Bonini, Chiara / Parmiani, Giorgio. · ·J Gene Med · Pubmed #22736622.

ABSTRACT: -- No abstract --

359 Editorial Just listen and think. 2012

Redberg, Rita F. · ·Arch Intern Med · Pubmed #22732743.

ABSTRACT: -- No abstract --

360 Editorial Warp, weft, and the tapestry of nature. 2012

Arnheiter, Heinz. · ·Pigment Cell Melanoma Res · Pubmed #22712569.

ABSTRACT: -- No abstract --

361 Editorial Stage IV melanoma. 2012

Porensky, Paul / Chiocca, E Antonio. · ·J Neurosurg · Pubmed #22702483.

ABSTRACT: -- No abstract --

362 Editorial Ipilimumab for advanced metastatic melanoma. 2012

Starz, Hans. · ·Expert Opin Biol Ther · Pubmed #22690756.

ABSTRACT: -- No abstract --

363 Editorial Promises from trametinib in RAF active tumors. 2012

Sausville, Edward A. · ·N Engl J Med · Pubmed #22663012.

ABSTRACT: -- No abstract --

364 Editorial Surgery for distant metastatic melanoma improves survival. 2012

Kroon, Bin B R. · ·Ann Surg Oncol · Pubmed #22588471.

ABSTRACT: -- No abstract --

365 Editorial The role of BRAF V600 mutation in melanoma. 2012

Ascierto, Paolo A / Kirkwood, John M / Grob, Jean-Jacques / Simeone, Ester / Grimaldi, Antonio M / Maio, Michele / Palmieri, Giuseppe / Testori, Alessandro / Marincola, Francesco M / Mozzillo, Nicola. ·Department of Melanoma, Istituto Nazionale Tumori Fondazione G, Pascale, Naples, Italy. paolo.ascierto@gmail.com ·J Transl Med · Pubmed #22554099.

ABSTRACT: BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. The first selective inhibitor of mutant BRAF, vemurafenib, after highly encouraging results of the phase I and II trial, was compared to dacarbazine in a phase III trial in treatment-naïve patients (BRIM-3). The study results showed a relative reduction of 63 % in risk of death and 74 % in risk of tumor progression. Considering all trials so far completed, median overall survival reached approximately 16 months for vemurafenib compared to less than 10 months for dacarbazine treatment. Vemurafenib has been extensively tested on melanoma patients expressing the BRAFV600E mutated form; it has been demonstrated to be also effective in inhibiting melanomas carrying the V600K mutation. In 2011, both FDA and EMA therefore approved vemurafenib for metastatic melanoma carrying BRAFV600 mutations. Some findings suggest that continuation of vemurafenib treatment is potentially beneficial after local therapy in a subset of patients with disease progression (PD). Among who continued vemurafenib >30 days after local therapy of PD lesion(s), a median overall survival was not reached, with a median follow-up of 15.5 months from initiation of BRAF inhibitor therapy. For patients who did not continue treatment, median overall survival from the time of disease progression was 1.4 months. A clinical phase I/II trial is evaluating the safety, tolerability and efficacy of vemurafenib in combination with the CTLA-4 inhibitor mAb ipilimumab. In the BRIM-7 trial vemurafenib is tested in association with GDC-0973, a potent and highly selective inhibitor of MEK1/2. Preliminary data seem to indicate that an additional inhibitor of mutated BRAF, GSK2118436, might be also active on a wider range of BRAF mutations (V600E-K-D-R); actually, treatment with such a compound is under evaluation in a phase III study among stage III-IV melanoma patients positive for BRAF mutations. Overall, BRAF inhibitors were well tolerated; common adverse events are arthralgia, rash, fatigue, alopecia, keratoacanthoma or cutaneous squamous-cell carcinoma, photosensitivity, nausea, and diarrhea, with some variants between different inhibitors.

366 Editorial Gender disparities in patients with melanoma: breaking the glass ceiling. 2012

Sondak, Vernon K / Swetter, Susan M / Berwick, Marianne A. · ·J Clin Oncol · Pubmed #22547593.

ABSTRACT: -- No abstract --

367 Editorial Method to our madness or madness in our methods? Pitfalls in trial methodology. 2012

Levine, Mark N / Juergens, Rosalyn. · ·J Clin Oncol · Pubmed #22547587.

ABSTRACT: -- No abstract --

368 Editorial New melanoma treatments: a panacea or a Pandora's box? 2012

Mariwalla, Kavita. · ·Cutis · Pubmed #22530324.

ABSTRACT: -- No abstract --

369 Editorial Skin cancer: prevention and latest treatments. 2012

Saini, Ritu. · ·J Drugs Dermatol · Pubmed #22527423.

ABSTRACT: -- No abstract --

370 Editorial Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review. 2012

Larkin, J M G / Fisher, R A / Gore, M E. · ·Clin Oncol (R Coll Radiol) · Pubmed #22521078.

ABSTRACT: -- No abstract --

371 Editorial Reducing death from melanoma and standards of evidence. 2012

Weinstock, Martin A. · ·J Invest Dermatol · Pubmed #22499029.

ABSTRACT: -- No abstract --

372 Editorial Sentinel lymph node biopsy for thin melanoma-con. 2012

Sabel, Michael S. · ·J Surg Oncol · Pubmed #22488561.

ABSTRACT: -- No abstract --

373 Editorial Publication and interpretation of clinical trial results: the need for caution. 2012

Thompson, J F / Hong, A / Fogarty, G. · ·Ann Surg Oncol · Pubmed #22476820.

ABSTRACT: -- No abstract --

374 Editorial Public health and the tanning bed controversy. 2012

Brady, Mary S. · ·J Clin Oncol · Pubmed #22473156.

ABSTRACT: -- No abstract --

375 Editorial Early [18F]fluorodeoxyglucose-positron emission tomography responses in metastatic melanoma: what do they mean? 2012

Millward, Michael J. · ·J Clin Oncol · Pubmed #22454416.

ABSTRACT: -- No abstract --

Back · Next